Scinai Immunotherapeutics

Scinai Immunotherapeutics

The leading #UniversalFluVaccine candidate: Designed for multi-season multi-strain protection from seasonal & pandemic influenza; Phase 3 trial. (NASDAQ: $BVXV).

HQ location
Jerusalem, Israel
Website
scinai.com
Launch date
Employees
11-50 people
Market cap
$4.3m
Enterprise value
$21m
Share price
$0.64 BVXV
Company register number
513436105
Recent deals
https://twitter.com/biondvaxhttp://www.facebook.com/pages/BiondVax-Pharmaceuticals-Ltd/180228491998332https://www.linkedin.com/company/scinai/scinai.immunotherapeutics
    • Edit
loading funding rounds…
Office of the Chief Scientist
Office of the Chief Scientist(exited)
European Investment Bank
European Investment Bank(exited)
Aegis Venture Funds
Aegis Venture Funds(exited)
YA II PN
YA II PN(exited)

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
ILS201720182019202020212022
Revenues000000000000000000000000
EBITDA000000000000000000000000
Profit000000000000000000000000
EV000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget000000000000000000000000

Source: Company filings or news article

Related Content

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Scinai Immunotherapeutics

Edit
PinCell
PinCell
ACQUISITION by Scinai Immunotherapeutics Mar 2025